Stock Analysis

Azenta Full Year 2023 Earnings: Beats Expectations

NasdaqGS:AZTA
Source: Shutterstock

Azenta (NASDAQ:AZTA) Full Year 2023 Results

Key Financial Results

  • Revenue: US$665.1m (up 20% from FY 2022).
  • Net loss: US$12.9m (loss widened by 14% from FY 2022).
  • US$0.19 loss per share (further deteriorated from US$0.15 loss in FY 2022).
earnings-and-revenue-growth
NasdaqGS:AZTA Earnings and Revenue Growth November 15th 2023

All figures shown in the chart above are for the trailing 12 month (TTM) period

Azenta Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 1.4%. Earnings per share (EPS) also surpassed analyst estimates by 45%.

Looking ahead, revenue is forecast to grow 5.9% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Life Sciences industry in the US.

Performance of the American Life Sciences industry.

The company's shares are up 11% from a week ago.

Risk Analysis

Don't forget that there may still be risks. For instance, we've identified 1 warning sign for Azenta that you should be aware of.

If you're looking to trade Azenta, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.

With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.

Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.

Sponsored Content

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About NasdaqGS:AZTA

Azenta

Provides biological and chemical compound sample exploration and management solutions for the life sciences market in the United States, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally.

Flawless balance sheet and undervalued.